Full text is available at the source.
Abstract
Incretin-based pharmacotherapies may lead to substantial weight loss through appetite suppression and reduced energy intake.
- Weight loss is associated with mechanisms such as appetite suppression and gastrointestinal effects.
- These therapies could modify dietary intake and gastrointestinal physiology.
- Long-term treatment raises concerns regarding potential micronutrient disturbances.
- Metabolic adaptations related to weight loss may also be affected by these pharmacotherapies.
Simplified